Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

Official Title

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy

Keywords

Non-obstructive Hypertrophic Cardiomyopathy Cardiomyopathies Cardiomyopathy, Hypertrophic Hypertrophy IMB-1018972 IMB-1018972 200mg

Eligibility

You can join if…

Open to people ages 18-75

  • Diagnosis of Hypertrophic Cardiomyopathy consistent with current US and European guidelines
  • Ability to perform an upright treadmill cardiopulmonary exercise test
  • Agreement to abide by contraceptive requirements

You CAN'T join if...

  • Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability
  • Women who are pregnant, planning to become pregnant or lactating
  • Participation in another clinical study involving a test product or invasive medical device within 28 days (or within 5 elimination half-lives of the respective test product, whichever is longer), prior to first dosing

Locations

  • Imbria Investigational Site not yet accepting patients
    San Francisco California 94143 United States
  • Imbria Investigational Site not yet accepting patients
    Portland Oregon 97239 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Imbria Pharmaceuticals, Inc.
ID
NCT04826185
Phase
Phase 2
Study Type
Interventional
Last Updated